

Date: 03 February 2025

То

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051

NSE Scrip Symbol: SaiLife

To **BSE Limited**

Phiroze Jeejeebhoy Towers, Dalal Street

Mumbai – 400001

BSE Scrip Code: 544306

Sub: Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company is hosting the Earnings Conference call on Friday, 07 February 2025 at 4:30 PM (IST) for discussing Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2024.

Complete details of the Earnings Conference call are attached herewith for your reference.

We request you to take note of the same and oblige.

Thank you.

For Sai Life Sciences Limited

Runa Karan
Company Secretary & Compliance Officer
Membership No.: A13721

Encl: As above



Sai Life Sciences Q3FY25 Results Conference Call At 4.30 pm IST on February 7, 2025 (Friday)

We are pleased to invite you to Sai Life Sciences Q3FY25 results conference call with the senior management. The conference call will be held on Friday, February 7, 2025, at 4:30 PM (IST). The call will be initiated with a brief management discussion on the earnings performance followed by an interactive Question & Answer session

The details of the earnings call are:

Date: February 7, 2025. Time Slot (IST): 4:30 PM – 6:00 PM

Dial-in Number: +91 22 6280 1107, +91 22 7115 8008

Other Dial in Numbers:

International Toll Free: USA: 8667462133 | UK: 08081011573 | Singapore: 8001012045 |

Hong Kong: 800964448

Pre-Registration Facility for the call and dial in directly without waiting for the operator: Click Here

Or Copy this URL in your browser:

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=8252975&linkSecurityString=393a3b4fca

Management Representation from Sai Life Sciences Business Services

Mr. Krishna Kanumuri, Managing Director & Chief Executive Officer

Mr. Siva Chittor, Chief Financial Officer

About Sai Life Sciences Business Services

Sai Life Sciences a pureplay fully integrated, innovator focused, Contract Research and Development Organization (CRDMO). It served a diverse customer base of 280+ innovator pharmaceutical companies that includes global pharmaceutical companies and biotechnology firms in FY24. Its clientele includes 18 out of Top 25 pharmaceutical companies, in terms of revenue for the calendar year 2023, across regulated markets, including the US, the UK, Europe and Japan. They provide end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities. The company has a strong portfolio of drug discovery and development and commercialization services supported by over 2,800 employees across India, US, UK, and Japan. Sai is one of the few CRDMOs to have differentiated delivery model of having research labs for discovery and development located near overseas major overseas innovation hubs at Watertown (Greater Boston, MA), United States and Manchester, United Kingdom, complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India.

For further information please contact: lnvestorrelation@sailife.com